Quantum Biopharma (QNTM) Income from Non-Controlling Interests (2019 - 2026)

Quantum Biopharma's Income from Non-Controlling Interests history runs 8 years deep, the most recent figure standing at -$13.8 million for Q1 2026.

• In Q1 2026, Income from Non-Controlling Interests fell 257.37% year-over-year to -$13.8 million; the TTM figure through Mar 2026 stood at -$58.9 million (down 1593.64% YoY), while the FY2025 annual figure was -$27.0 million, down 80.73% from the prior year.
• Income from Non-Controlling Interests came in at -$13.8 million for Q1 2026 at Quantum Biopharma, up from -$50.2 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $25.4 million in Q2 2023 to a low of -$50.2 million in Q4 2025.
• A 5-year average of -$5.1 million and a median of -$2.7 million in 2024 frame the typical range for Income from Non-Controlling Interests.
• On a YoY basis, Income from Non-Controlling Interests climbed as much as 517.89% in 2025 and fell as far as 820.24% in 2025.
• Quantum Biopharma's Income from Non-Controlling Interests stood at $5.9 million in 2022, then slumped by 689.46% to -$34.8 million in 2023, then soared by 84.33% to -$5.5 million in 2024, then tumbled by 820.24% to -$50.2 million in 2025, then surged by 72.61% to -$13.8 million in 2026.
• According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$13.8 million, -$50.2 million, and -$4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison